Business Context and Reporting Period
Company: Sana Biotechnology, Inc. (SANA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Sana is a clinical-stage biotechnology company developing engineered cell therapies using two proprietary platforms: ex vivo hypoimmune (HIP) technology to create allogeneic cells that evade immune rejection, and in vivo fusogen technology to deliver genetic payloads directly to cells within the body. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Loss | $(244.2) million | $(266.8) million | $(283.3) million |
| Total Operating Expenses | $250.3 million | $272.7 million | $293.1 million |
| Research & Development (R&D) Expenses | $132.0 million | $215.7 million | $261.8 million |
| General & Administrative (G&A) Expenses | $44.3 million | $64.0 million | $73.3 million |
| Impairment of Long-Lived Assets | $44.6 million | $1.9 million | $7.0 million |
| Cash, Cash Equivalents, and Marketable Securities | $138.4 million | $152.5 million | $187.3 million |
| Accumulated Deficit | $(1.8) billion | $(1.6) billion | $(1.3) billion |
Note: The filing text does not provide a specific value for "Revenue" as the company has no commercial products. Interest income was $3.8 million for 2025.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $22.4 million (8.2%) compared to 2024. R&D expenses dropped significantly by $83.7 million, primarily due to a portfolio prioritization in late 2024 that reduced headcount and the scope of research activities.
- Impairment Charges: A significant non-cash impairment charge of $44.6 million was recorded in 2025, compared to $1.9 million in 2024. This was driven by the decision to suspend the build-out of internal manufacturing capabilities at the Bothell, WA facility and sublease portions of the Seattle facility.
- Success Payment Liabilities: Expenses related to the change in fair value of success payment liabilities and contingent consideration increased to $29.4 million in 2025 (expense) from a gain of $8.9 million in 2024, driven by fluctuations in market capitalization and stock price.
- Capital Raises: The company raised approximately $126.4 million in net proceeds from equity financings in 2025, including an August 2025 underwritten offering and at-the-market sales.
Guidance, Outlook, and Risks
Strategic Prioritization
In November 2025, Sana announced a portfolio prioritization to focus resources on two lead programs:
- SC451 (Ex Vivo): A HIP-modified, stem cell-derived pancreatic islet cell therapy for Type 1 Diabetes. The company expects to submit an Investigational New Drug (IND) application and begin Phase 1 trials as early as 2026. Recent 12-month data from the UP421 investigator-sponsored trial demonstrated durable survival and function of transplanted cells without immunosuppression.
- SG293 (In Vivo): An in vivo CAR T product candidate for B cell malignancies and autoimmune diseases. Preclinical data in non-human primates showed robust CAR T generation and deep B cell depletion. The company expects to generate initial clinical data as early as 2026.
Development of two allogeneic CAR T programs (SC291 and SC262) was suspended to conserve capital.
Going Concern Warning
Management has determined that there is substantial doubt about the company's ability to continue as a going concern. Current capital resources ($138.4 million) are not sufficient to fund planned operations for at least one year from the filing date. The company will require additional financing to execute its business plan.
Key Risks
- Capital Requirements: Failure to raise additional capital on acceptable terms could force the company to delay, reduce, or eliminate product development programs.
- Regulatory Uncertainty: Novel technologies (stem cells, gene editing) face complex and unpredictable regulatory pathways. The FDA has not yet approved a therapeutic derived from stem cells.
- Manufacturing Complexity: Reliance on third-party CDMOs and the complexity of scaling cell therapies pose significant risks to timelines and costs.
- Intellectual Property: The company relies on in-licensed IP from Harvard, UCSF, Washington University, and others. Breach of these agreements could result in loss of rights.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $138.4 million cash balance against the burn rate and the timeline for the next equity raise.
- Manufacturing Strategy: Confirm the status of the Bothell facility sublease and the specific CDMO partnerships for SC451 and SG293 clinical supply.
- UP421 Trial Data: Review the full 12-month data from the UP421 investigator-sponsored trial published in The New England Journal of Medicine to validate the immune evasion claims.
- Success Payment Triggers: Monitor stock price and market capitalization thresholds that could trigger significant cash or stock payments to Harvard and Cobalt Biomedicine.
- Legal Proceedings: Track the status of the securities class action litigation filed in March 2025 regarding statements about the SC291 program.